Following Investment, MedPharm Ltd Strengthens its Board with Three New Members

MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to introduce three new members to its Board of Directors.

MedPharm has announced the appointment of three new members to its Board of Directors following an investment by Ampersand Capital Partners (“Ampersand”) in the Company earlier this year. Two of the new Non-Executive Directors are members of the Ampersand investment team: David Parker, General Partner, and Trevor Wahlbrink, Partner. The third Non-Exective Director appointment is Patrick Walsh, who is currently the CEO of Avista Pharma Solutions, a pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Durham, North Carolina.

All have in-depth experience in the healthcare sector and have served on the boards of multiple CDMO businesses. 

‘We are very pleased to have David, Trevor and Patrick joining MedPharm’s board’, stated CEO Andy Muddle. ‘They bring a wealth of experience which will be highly beneficial to MedPharm as it continues its impressive growth. Their wisdom and oversight will be invaluable to the business as we expand globally into new markets’.

Share this article

More services


This article is featured in:
Companies and People


Comment on this article

You must be registered and logged in to leave a comment about this article.